Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users

S Staszewski; A Haberl; P Gute; G Nisius; V Miller; A Carlebach

Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users

Antivir Ther. 1998:3 Suppl 4:55-6.

Authors

S Staszewski¹, A Haberl, P Gute, G Nisius, V Miller, A Carlebach

Affiliation

¹ Klinikum der JW Goethe-Universität Frankfurt, Zentrum der Inneren Medizin, Germany. [email protected]

PMID: 10723511

Abstract

Human immunodeficiency virus (HIV)-infected, active intravenous drug users received once-daily therapy consisting of a combination of didanosine (2',3'-dideoxyinosine or DDI), lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine or 3TC] and nevirapine. Preliminary results for the first 24 weeks show that the regimen provides potent immunological and antiviral effects.

Publication types

Clinical Trial

MeSH terms

Adult
CD4 Lymphocyte Count
Didanosine / administration & dosage*
Drug Therapy, Combination
Female
HIV Infections / complications
HIV Infections / drug therapy*
HIV-1*
Humans
Lamivudine / administration & dosage*
Male
Methadone / therapeutic use
Nevirapine / administration & dosage*
Pilot Projects
Prospective Studies
Substance Abuse, Intravenous / complications*
Substance Abuse, Intravenous / drug therapy
Viral Load

Substances

Lamivudine
Nevirapine
Didanosine
Methadone